Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that enrollment in its Phase 3 APPROACH clinical trial evaluating HLP003 for the adjunctive treatment of major depressive disorder has surpassed 86% and remains on track. The study is one of the company’s Phase 3 trials supporting development of HLP003, its lead proprietary novel serotonergic agonist, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
The APPROACH study is part of Helus Pharma’s broader Phase 3 PARADIGM program, which also includes the EMBRACE study and the EXTEND long-term extension study. The company said the enrollment milestone supports its goal of reporting topline data from APPROACH in the fourth quarter of 2026 as it advances HLP003 toward potential commercialization for patients with major depressive disorder. For the full press release, visit https://ibn.fm/Qpikw.
Major depressive disorder affects millions worldwide, and current treatments often have limited efficacy or significant side effects. HLP003, a novel serotonergic agonist, is designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering durable improvements in mental health. The Breakthrough Therapy Designation from the FDA underscores the drug’s potential to address the large unmet need for effective adjunctive treatments.
The significance of this enrollment milestone cannot be overstated. Reaching 86% enrollment ahead of schedule suggests strong patient interest and efficient trial execution. If APPROACH and the broader PARADIGM program yield positive results, HLP003 could become a new standard of care for patients who do not respond adequately to existing antidepressants. This would not only impact the lives of millions but also reshape the competitive landscape in the psychiatric pharmaceutical market.
Investors and stakeholders are closely watching Helus Pharma’s progress. The company also has HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder, along with an extensive research portfolio of investigational NSAs. For company updates, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Latest news and updates relating to HELP are available at https://ibn.fm/HELP.
The rapid enrollment progress suggests that the APPROACH trial could deliver results sooner than anticipated, potentially accelerating the timeline for regulatory submissions and eventual market entry. For patients and clinicians alike, this brings hope that a new, effective treatment for major depressive disorder may be on the horizon.
